Company Profile
HOOKIPA Pharma Inc. Stock Price, News & Catalysts
- Ticker:
- HOOK
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.15 USD (+0.88%)
Close
Last updated: June 2, 2026
—
Market cap
Why the stock is moving
Current closing-price context is not available for HOOK.
Company overview
Arenaviral Immunotherapy Platform
HOOKIPA Pharma develops immunotherapies using engineered arenavirus vectors designed to generate strong antigen-specific T-cell responses. The platform supports both oncology programs and partnered infectious-disease vaccines.
HB-700 for KRAS-Mutated Cancers
HB-700 is a multi-antigen therapy directed at common KRAS mutations across lung, colorectal, pancreatic, and other cancers. The program uses repeated administration of complementary vectors to sustain immune activity against tumor antigens.
Clinical Proof from Eseba-Vec
The HB-700 strategy is supported by clinical experience with eseba-vec, formerly HB-200, in HPV16-positive head and neck cancer. That program demonstrated the platform's ability to induce antigen-specific immune responses in patients with advanced cancer.
Partnered Infectious-Disease Programs
HOOKIPA has collaborated with Gilead on arenaviral immunotherapies for hepatitis B and HIV. Partner funding and milestone economics provide a second business model alongside internally led oncology development.
Portfolio Prioritization
The company has paused or divested selected programs to focus capital on its highest-priority assets and collaborations. Its development model relies on specialized vector engineering, outsourced manufacturing, and external clinical networks.
Future catalysts
- Interim Phase 1 data from HB-700 in KRAS-mutated cancers in the first half of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of HOOKIPA Pharma Inc. (HOOK)?
HOOKIPA Pharma Inc. (HOOK) most recently closed at 1.15 USD, a +0.88% move versus the previous session.
What does HOOKIPA Pharma Inc. do?
Arenaviral Immunotherapy Platform HOOKIPA Pharma develops immunotherapies using engineered arenavirus vectors designed to generate strong antigen-specific T-cell responses. The platform supports both oncology programs and partnered infectious-disease vaccines. HB-700 for KRAS-Mutated Cancers HB-700 is a multi-antigen therapy directed at common KRAS...
On which exchange is HOOK stock listed?
HOOKIPA Pharma Inc. (HOOK) is associated with NASDAQ, United States, Biopharma.
What is HB-700?
Interim Phase 1 data from HB-700 in KRAS-mutated cancers in the first half of 2026.
Which conditions is HOOKIPA Pharma Inc. targeting with HB-700?
HOOKIPA Pharma Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does HOOKIPA Pharma Inc. describe recent progress with HB-700?
Interim Phase 1 data from HB-700 in KRAS-mutated cancers in the first half of 2026.
What is HB-200?
Clinical Proof from Eseba-Vec The HB-700 strategy is supported by clinical experience with eseba-vec, formerly HB-200, in HPV16-positive head and neck cancer.
What should investors watch for with HB-200?
Interim Phase 1 data from HB-700 in KRAS-mutated cancers in the first half of 2026.